Discussion Topics:

• Identification of the clinical settings/indications for personalised cancer vaccines
• Strategies to enhance vaccine immunogenicity and effectiveness
• Overcoming challenges in personalised cancer vaccine manufacture, release and supply

Discussion Leaders:

• Elisa Scarselli, Chief Scientific Officer, Nouscom
• Eric Halioua, President & Chief Executive Officer,  PDC*line Pharma
• Loredana Siani, Vice President Technical and CMC Development, Nouscom

Discussion Topics:

• Improving ADC therapeutic index – analytical tools for assessing tolerability and efficacy
• Assays for evaluating ADC efficacy – models for efficacy assessment
• Minimising ADC toxicities
  • Analysing aggregation to avoid toxicity
  • Evaluating plasma stability methods

Discussion Leaders:

• Mahendra Deonarain, CEO, Antikor Biopharma
• Ioanna Stamati, Team Leader Bioconjugation, Antikor Biopharma

Discussion Topics:

• Green chemistry and sustainability in peptide development
• Facilitating industiral-academic collaboration for peptide lead translation towards the clinical setting

Discussion Leaders:

• William Lubell, Professor, University of Montreal
• Wu Su, Director of Medicinal Chemistry, Astrazeneca

Discussion Topics:

• Exploring novel bispecific formats
• The capabilities of multispecifics
• Overcoming the challenges of bispecific development

Discussion Leaders:

• Zhiying Li, Director of Life Sciences & Technology, GemPharmatech
• Peter Ellmark, CSO,  Alligator Bioscience

Discussion Topics:

• Factors important in antibody discovery for ADCs
• What are the beenfits of different conjugation methods?
• Are the ultra-potent payloads limited to haematological cancers? Are camptothecins set to dominate?
• ADC development for solid tumours and other indications

Discussion Leaders:

• Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma Ltd

Discussion Topics:

• What are the available approaches and/or opportunities of control and specification development for oligonucleotides?
• What are the regulatory considerations around specifications for oligonucleotides?

Discussion Leaders:

• Ilias Jimidar, Associate Director of Analytical Integration, Janssen R&D
• Ahmed Elmekawy, Associate Principal Scientist, Oligonucleotides Project Lead, AstraZeneca

Discussion Topics:

• AI-driven single protein structure prediction
• AI-driven protein-protein interaction prediction
• Available computational tools for early biologics discovery and development

Discussion Leader:

• Leonardo De Maria, Principal Scientist at AstraZeneca 
• Origène Nyanguile, Professor, University of Applied Sciences Western Switzerland